Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,368
datasets available to search
ShareScore release 0.9.0
Dataset results
1,368 results for “kidney transplantation”
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
ClinicalTrials.gov study NCT00906204. IPD Sharing: Not stated. Countries: 1. Publications: 3.
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
ClinicalTrials.gov study NCT03615235. IPD Sharing: YES. Countries: 1. Publications: 11.
Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
ClinicalTrials.gov study NCT02743897. IPD Sharing: UNDECIDED. Countries: 1. Publications: 9.
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
ClinicalTrials.gov study NCT04605484. IPD Sharing: NO. Countries: 1. Publications: 4.
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
ClinicalTrials.gov study NCT01953120. IPD Sharing: NO. Countries: 1. Publications: 1.
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
ClinicalTrials.gov study NCT03923556. IPD Sharing: NO. Countries: 1. Publications: 0.
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients
ClinicalTrials.gov study NCT01157234. IPD Sharing: Not stated. Countries: 1. Publications: 19.
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
ClinicalTrials.gov study NCT03468478. IPD Sharing: NO. Countries: 1. Publications: 1.
Improved Selection of Elderly (> 65 Years) for Kidney Transplantation
ClinicalTrials.gov study NCT01760733. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification
ClinicalTrials.gov study NCT01541384. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation
ClinicalTrials.gov study NCT05730257. IPD Sharing: NO. Countries: 1. Publications: 1.
Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
ClinicalTrials.gov study NCT00284934. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
ClinicalTrials.gov study NCT02444143. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
ClinicalTrials.gov study NCT01178216. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
ClinicalTrials.gov study NCT01594424. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
ClinicalTrials.gov study NCT03611621. IPD Sharing: NO. Countries: 3. Publications: 0.
Influence of polymorphisms in the vascular endothelial growth factor gene on allograft rejection after kidney transplantation: a meta-analysis
Open the record for dataset details and reuse information.
Kidney transplantation waiting times and risk of cardiovascular events and mortality: a retrospective observational cohort study in Taiwan
Open the record for dataset details and reuse information.
Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
<p class="BodyText31"><u>Background:</u> Induction therapy is crucial in kidney transplantation and constitutes an important cornerstone for long-term allograft survival. Alemtuzumab is a depleting CD52-specific antibody with T and B cell activity, leading to prolonged lymphocyte depletion for up to 12 months, with profound immunosuppression and an associated risk of serious infections. Current concepts aim to optimize dosing strategies to reduce side effects. Here we present data from an ongoing centre protocol consisting of low-dose alemtuzumab induction and tailored immunosuppression in sensitized patients undergoing kidney transplantation.</p> <p><u>Methods:</u> 10-year results of the protocol were analysed. Low-dose alemtuzumab induction consisted of a single dose of 20mg intraoperatively, followed by tacrolimus and corticosteroids for initial immunosuppression, with mycophenolate mofetil suspended until a total lymphocyte count >5% or 200/µl was reached.</p> <p><u>Results:</u> Between 01/2007 and 04/2017, 46 patients were treated in accordance with the protocol in 48 kidney transplantations. Median PRA<sub>max</sub> was 43 [22-76; IQR] %; all patients had negative CDC-crossmatch prior to transplantation. Low-dose alemtuzumab was well tolerated. Median time to TLC recovery was 77 [62-127; IQR] d. Within a median follow-up of 3.3 [1.5-5.6; IQR] years, 12 (25%) patients developed BPAR, 10 of which were antibody-mediated (3 acute, 7 chronic ABMR). Death-censored 5-year allograft survival was 79.2%, with an excellent allograft function at the end of follow-up. There was no increased rate of infections, in particular viral infections.</p> <p><u>Conclusions</u>: Our protocol, comprising low-dose alemtuzumab induction, initial suspension of mycophenolate mofetil and triple maintenance immunosuppression, provides excellent patient and allograft outcome in sensitized renal allograft recipients.</p>
Data from: If you build it, they may not come: modifiable barriers to patient portal use among pre- and post-kidney transplant patients
Background: Patient access to health information using electronic patient portals is increasingly common. Portal use has the potential to improve patients' engagement with their health and is particularly important for patients with chronic illness; however, patients' abilities, attitudes, and use of portals is poorly understood. Methods: A single-center, cross-sectional survey was conducted of 240 consecutive pre- and post-kidney transplant patients of all levels of technological proficiency who presented to an urban transplant center in the United States. The Patient Information and Technology Assessment-Patient Portal (PITA-PP) was used to assess patients' attitudes toward the use of patient portals. Results: Most patients surveyed did not use the patient portal (n = 176, 73%). Patients were more likely to use the patient portal if they were White, highly educated, in the post-transplant period, more comfortable with technology, and reported being a frequent internet user (p < 0.05). The most common reasons for not using the patient portal included: (1) preference for traditional communication, (2) not being aware of the portal, (3) low technological proficiency, and (4) poor interoperability between the portal at the transplant center and the patient's primary care center. Conclusions: We identified several modifiable barriers to patient portal use. Some barriers can be addressed by patient education and training on portal use, and federal initiatives are underway to improve interoperability; however, a preference for traditional communications represents the most prominent barrier. Additional strategies are needed to improve portal adoption by encouraging acceptance of technologies as a way of clinical communication.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.